DEMANT Demant A/S
Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.…
Industry Peers
Medical DevicesKey Statistics
About Demant (CPH: DEMANT)
›
Demant (CPH: DEMANT) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 26,616 employees.
The shares were at 345.00 DKK on 19 November 2026, up 55.4% over 52 weeks. Its 52-week range is 175.00 DKK to 386.00 DKK: the price is 10.6% below the high and 97.1% above the low.
At a market capitalisation of 72.76B DKK, it trades at 30.1 times trailing earnings and 19.8 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.4, a premium of 18% for DEMANT.
Demant reports return on equity of 15.7%, an operating margin of 17.2% and revenue up 14.8% year over year.
Its debt exceeds its cash by 18.79B DKK, a debt-to-equity ratio of 2.13. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 20 analysts cover the stock, with an average rating of Buy; their mean price target of 359.85 DKK is 4.3% above the current price. The next earnings report is expected on 2 February 2027.